Literature DB >> 17974522

Molecular biology of myeloma.

N C Gutiérrez1, R García-Sanz, J F San Miguel.   

Abstract

Multiple myeloma (MM) is a B-cell malignancy characterised by the accumulation of clonal plasma cells (PC) in the bone marrow (BM). The molecular bases for this incurable disease have been widely investigated in the last years, and the development of modern genomic technologies has contributed to the understanding of the pathogenesis of MM. The molecular mechanisms that explain the cellular origin of myeloma cells, the cytogenetic abnormalities and their clinical implications, and the biological information provided by gene expression profiling analysis are reviewed in this paper. In addition, a molecular classification of MM in seven groups based on the relationship between gene expression profiling, chromosomal translocations and prognostic outcome is also presented. And finally, the recent hypothesis of a potential unifying event in the pathogenesis of MM, supported by cyclin D deregulation in virtually all MM tumours, will be summarised.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17974522     DOI: 10.1007/s12094-007-0114-4

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  57 in total

Review 1.  Lymphoid malignancies: the dark side of B-cell differentiation.

Authors:  A L Shaffer; Andreas Rosenwald; Louis M Staudt
Journal:  Nat Rev Immunol       Date:  2002-12       Impact factor: 53.106

2.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.

Authors:  M Chesi; E Nardini; L A Brents; E Schröck; T Ried; W M Kuehl; P L Bergsagel
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

3.  Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.

Authors:  J Shaughnessy; A Gabrea; Y Qi; L Brents; F Zhan; E Tian; J Sawyer; B Barlogie; P L Bergsagel; M Kuehl
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

4.  p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance.

Authors:  G Guillerm; E Gyan; D Wolowiec; T Facon; H Avet-Loiseau; K Kuliczkowski; F Bauters; P Fenaux; B Quesnel
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

5.  A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.

Authors:  Wee Joo Chng; Scott A Van Wier; Gregory J Ahmann; Jerry M Winkler; Syed M Jalal; Peter Leif Bergsagel; Marta Chesi; Mike C Trendle; Martin M Oken; Emily Blood; Kim Henderson; Rafael Santana-Dávila; Robert A Kyle; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Rafael Fonseca
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

6.  Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping.

Authors:  J R Sawyer; J L Lukacs; N Munshi; K R Desikan; S Singhal; J Mehta; D Siegel; J Shaughnessy; B Barlogie
Journal:  Blood       Date:  1998-12-01       Impact factor: 22.113

7.  Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.

Authors:  M Chesi; P L Bergsagel; O O Shonukan; M L Martelli; L A Brents; T Chen; E Schröck; T Ried; W M Kuehl
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

8.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

Authors:  Jonathan J Keats; Tony Reiman; Christopher A Maxwell; Brian J Taylor; Loree M Larratt; Michael J Mant; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

9.  Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.

Authors:  G Tricot; B Barlogie; S Jagannath; D Bracy; S Mattox; D H Vesole; S Naucke; J R Sawyer
Journal:  Blood       Date:  1995-12-01       Impact factor: 22.113

10.  Genetics and cytogenetics of multiple myeloma: a workshop report.

Authors:  Rafael Fonseca; Bart Barlogie; Regis Bataille; Christian Bastard; P Leif Bergsagel; Marta Chesi; Faith E Davies; Johannes Drach; Philip R Greipp; Ilan R Kirsch; W Michael Kuehl; Jesus M Hernandez; Stephane Minvielle; Linda M Pilarski; John D Shaughnessy; A Keith Stewart; Herve Avet-Loiseau
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

View more
  4 in total

1.  Calorimetric markers for monitoring of multiple myeloma and Waldenström's macroglobulinemia patients.

Authors:  Svetla Todinova; Sashka Krumova; Avgustina Danailova; Violeta Petkova; Margarita Guenova; Georgi Mihaylov; Lidia Gartcheva; Stefka Germanova Taneva
Journal:  Eur Biophys J       Date:  2018-01-23       Impact factor: 1.733

2.  Deficient spindle assembly checkpoint in multiple myeloma.

Authors:  Elena Díaz-Rodríguez; Stela Álvarez-Fernández; Xi Chen; Bruno Paiva; Ricardo López-Pérez; Juan Luis García-Hernández; Jesús F San Miguel; Atanasio Pandiella
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

3.  Characterization of monoclonal gammopathy of undetermined significance by calorimetric analysis of blood serum proteome.

Authors:  Francisca Barceló; Joan J Cerdà; Antonio Gutiérrez; Teresa Jimenez-Marco; M Antonia Durán; Andrés Novo; Teresa Ros; Antonia Sampol; José Portugal
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

Review 4.  Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications.

Authors:  Ignacio J Cardona-Benavides; Cristina de Ramón; Norma C Gutiérrez
Journal:  Cells       Date:  2021-02-05       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.